The frequency of CD80+ and CD155+ cancer cells increased in mixed and even more so in mesenchymal patient cSCCs (Fig. 2f–i), being in the latter tumors where CD80 and CD155 expression was mainly observed in cancer cells that lost E-cadherin expression (Fig. 2j, k). This evidence concerns the gene CD80 and cancer.